Indeed, the lower ADAMTS13 levels detected in MS patients (and in particular in MS patients with cerebral microbleeds) should stimulate further investigation based on potentially enhanced vWF activity in plasma, which has been suggested as a possible marker for evaluating the endothelial damage, leading to BBB breakdown. Here, VWF is linked to cerebral microbleeds.